Patients with heart failure (HF) and severe secondary mitral regurgitation (MR) frequently also suffer from baseline renal disease (RD). Renal function is further impaired by HF and MR, often accelerating progression to end-stage renal disease (ESRD), necessitating a form of renal replacement therapy (RRT). For patients with MR deemed too high-risk for surgery, the … [Read more...] about COAPT Trial: Renal dysfunction and cardiac outcomes in heart failure
Heart failure
Greater risk of death in heart failure patients hospitalized for COVID-19
The CAPACITY-COVID Collaborative Consortium and LEOSS Study Group examined outcomes of hospitalized COVID-19 patients, both with and without pre-existing heart disease. The CAPACITY-COVID (NCT04325412) registry was launched in March 2020 and has collected data from adults hospitalized for COVID-19 from 74 centres across 13 countries across Europe. The Lean Open Survey on … [Read more...] about Greater risk of death in heart failure patients hospitalized for COVID-19
Empagliflozin and Renal Outcomes in Heart Failure
The EMPEROR-Reduced (NCT03057977) and EMPEROR-Preserved (NCT03057951) trials demonstrated that empagliflozin could reduce the risk of hospitalization for heart failure (HF) both in patients with HF and reduced left ventricular ejection fraction (LVEF) and patients with HF and preserved LVEF. However, the effect of empagliflozin on renal function is unknown. Investigators … [Read more...] about Empagliflozin and Renal Outcomes in Heart Failure
Top Highlights of ACC 2022
The American College of Cardiology (ACC) 2022 Scientific Session was a hybrid event which took place from April 2 to 4, 2022, in Washington, USA and online. Here is the curated list of the top highlights of the ACC 2022 sessions. SODIUM-HF trial1: This international trial (NCT02012179) followed 806 adult patients with chronic heart failure (CHF) receiving optimally … [Read more...] about Top Highlights of ACC 2022
EMPEROR Preserved: Empagliflozin in heart failure with preserved ejection fraction
Patients with heart failure (HF) and a preserved (>40%) left ventricular ejection fraction (LVEF) have few therapeutic options. Sodium glucose cotransporter 2 inhibitors have been shown to reduce the risk of hospitalization for HF in patients with HF and a reduced LVEF. It is unknown if these drugs can provide a similar benefit for patients with HF with a preserved LVEF … [Read more...] about EMPEROR Preserved: Empagliflozin in heart failure with preserved ejection fraction